

1
2
3 Surgery does not improve reoperation risk or patient function compared to
4
5 nonoperative approaches for common fractures of the clavicle:
6
7

8 A systematic review and meta-analysis of randomized controlled trials
9
10

11
12 Tahira Devji BSc¹, Ydo Kleinlugtenbelt MD, PhD(Cand)², Nathan Evaniew MD,
13
14 PhD(Cand)^{1,2}, Bill Riskevski MD, MSc², Shoghag Khoudigian BSc¹, Mohit
15
16 Bhandari MD, PhD^{1,2}
17
18
19
20
21

- 22 1. Department of Clinical Epidemiology & Biostatistics, McMaster University.
23
24 293 Wellington St N Suite 110, Hamilton ON L8L 8E7
25
26
27 2. Division of Orthopaedic Surgery, McMaster University, 293 Wellington St
28
29 N Suite 110, Hamilton ON L8L 8E7
30
31
32
33
34
35
36
37
38
39
40

41 **Correspondence**

42
43 Mohit Bhandari MD, PhD, FRCSC

44
45 293 Wellington St N Suite 110

46
47
48 Hamilton ON L8L 8E7

49
50 bhandam@mcmaster.ca
51
52
53
54
55
56
57
58
59
60

ABSTRACT

Background: The popularity of surgery for acute displaced midshaft clavicle fractures has been fueled by early randomized controlled trials (RCTs) demonstrating improved radiographic union rates and perceived functional benefits over nonoperative approaches. We performed a meta-analysis to determine the relative effects of operative and nonoperative interventions in treating acute displaced midshaft clavicle fractures on secondary operations, all other complications, and long-term function.

Methods: We search MEDLINE, Embase and the Cochrane Library for reports of relevant RCTs published to March 7th, 2014. Two reviewers assessed the eligibility of potential reports and the risk of bias of included trials. The Grading of Recommendations Assessment, Development and Evaluation approach was used to summarize the quality of evidence for all outcomes.

Results: Fifteen RCTs were included (9 trials comparing operative versus nonoperative, 5 comparing implants for operative treatment, and 1 comparing nonoperative treatments). Nonoperative treatment did not differ from operative treatment in the risk of secondary operations (risk ratio (RR) 1.16, 95% confidence interval (CI) 0.58 to 2.35, p=0.67) or other complications (RR 0.90, 95% CI 0.55 to 1.50, p=0.70). One in four patients suffered a complication regardless of treatment approach. Functional outcome differences, although

1
2
3 smaller than the threshold for minimal important differences at 1 year, favored
4
5 operatively treated patients (standardized mean difference 0.38, 95% CI 0 to
6
7 0.75, $p=0.05$). Evidence for the type of implant or approach to nonoperative
8
9 treatment remained inconclusive.
10
11

12
13
14
15 **Interpretation:** Current evidence does not support routine surgery for displaced
16
17 midshaft clavicle fractures. Complication rates remain high regardless of
18
19 treatment approach.
20
21

22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Confidential

BACKGROUND

Clavicle fractures are common injuries affecting approximately 22,000 Canadians each year and 1.75 million fractures worldwide¹⁻⁶. The vast majority of these fractures are located in the midshaft, accounting for approximately 80% of all clavicle fractures^{1,2}. Traditionally closed midshaft clavicle fractures were treated nonoperatively, a practice largely based on previous studies by Neer and Rowe^{7,8}. In the last decade, evidence challenged the standard of nonoperative treatment, reporting high rates of nonunion (15-20%), poor early function, and up to 42% of patients experiencing residual sequelae at 6 months following nonoperative management⁹. Small clinical trials that followed have fueled a growing popularity to treat these fractures surgically with plates and screws or intramedullary devices; however, these procedures carry inherent surgical risks for infection, implant failure and hardware irritation requiring subsequent removal^{10,11}.

We performed a meta-analysis to determine the relative effects of operative and nonoperative interventions in treating acute displaced midshaft clavicle fractures with respect to rates of secondary operations, all other complications, and long-term function. Our study advances prior reviews by including new evidence from randomized controlled trials (RCTs), our focus on major health outcomes such as secondary operations within 1 year, and improved summary of evidence using Grading of Recommendations Assessment, Development, and Evaluation

1
2
3 (GRADE) to rate the quality of evidence available for each patient-focused
4
5
6 outcome.
7
8
9

10 **METHODS**

11
12 We conducted this study according to the methods outlined in the *Cochrane*
13 *Handbook for Systematic Reviews of Interventions*¹². Our findings are reported in
14
15 accordance with the Preferred Reporting Items for Systematic Reviews and
16
17 Meta-Analyses (PRISMA) statement¹³.
18
19
20
21
22
23
24

25 **Literature search**

26
27 We systematically searched MEDLINE, Embase, and the Cochrane Library for
28
29 articles published up to and including March 7th, 2014 (Appendix 1). MeSH and
30
31 Emtree headings were used in various combinations and supplemented with
32
33 free text (Appendix 1). An RCT filter developed by the Health Information
34
35 Research Unit (HIRU) at McMaster University¹⁴ was applied to the search. No
36
37 language or publication date restrictions were applied. Manual review of
38
39 reference lists of key articles, and use of the “related articles” feature in PubMed
40
41 were conducted to identify additional studies. We searched conference
42
43 proceedings (American Academy of Orthopaedic Surgeons, Canadian
44
45 Orthopaedic Association, Orthopaedic Trauma Association) from the last 5 years
46
47 and *Clinicaltrials.gov* to identify relevant unpublished studies.
48
49
50
51
52
53
54

55 **Study selection**

56
57
58
59
60

1
2
3 We included RCTs comparing any form of operative or nonoperative
4 interventions for acute displaced midshaft clavicle fractures in patients 16 years
5 of age or older. Thus, studies comparing operative versus nonoperative
6 interventions, studies comparing operative implants, as well as studies
7 comparing nonoperative interventions were considered. Two reviewers, both with
8 methodological expertise and one with content expertise independently, in
9 duplicate, screened titles and abstracts of identified citations from the electronic
10 search. Disagreements were carried forward for full text review. The full texts of
11 potentially eligible reports were independently evaluated in duplicate, and
12 disagreements were resolved through a consensus process to determine final
13 eligibility.
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31

32 **Data extraction and quality assessment**

33
34 The same two reviewers independently extracted data from included studies
35 using a piloted electronic data abstraction form. Authors of included studies were
36 contacted if important data were unclear or not reported. When information was
37 reported by graphical analyses only, the data were derived from the figures using
38 a graph digitizing software (GraphClick, Arizona Software, Switzerland).
39
40
41
42
43
44
45
46
47

48 The primary outcomes for this review were secondary operations, all other
49 complications, and long-term function (1 year or longer). Routine hardware
50 removal was not included as a secondary operation; only those that had an
51 indication for removal such as, infection, irritation or implant failure were counted.
52
53
54
55
56
57
58
59
60

1
2
3 Complications included symptomatic malunion, symptomatic nonunion, loss of
4 primary reduction, hardware irritation, infection, neurologic symptoms, or other
5 issues requiring surgical treatment. The selected complications were chosen as
6 they are considered to be patient-focused outcomes or were commonly reported
7 in the identified primary studies.
8
9

10
11
12
13
14
15
16
17 For the assessment of methodological quality, both reviewers independently
18 assessed the risk of bias of included trials using the Cochrane Risk of Bias tool¹².
19 They evaluated the quality of evidence in included trials using the GRADE
20 approach¹⁵. Data from RCTs were considered high-quality evidence, but could
21 have been rated down according to risk of bias, inconsistency, imprecision,
22 indirectness, or publication bias.
23
24
25
26
27
28
29
30
31
32
33

34 **Data synthesis**

35
36 Studies comparing operative implants, as well as studies comparing
37 nonoperative interventions were summarized quantitatively using risk ratios
38 (RRs) for secondary operations and all other complications. Mean differences
39 (MDs) were calculated for functional outcome scores.
40
41
42
43
44
45
46
47

48 Operative versus nonoperative trials were pooled in a meta-analysis. We pooled
49 data on secondary operations and all other complications from only trials that
50 completely reported these outcomes, and calculated RRs using the Mantel-
51 Haenszel method and a random effects model¹². We performed a 'none has
52
53
54
55
56
57
58
59
60

1
2
3 event' analysis, a variation of 'analysis-as-randomized'¹⁶. All patients randomized
4
5 comprised the denominator but those that were lost to follow-up (LTFU) were
6
7 assumed to not have had an event¹⁶. We performed two sensitivity analyses to
8
9 investigate the effects of dropouts and exclusions: 1) complete-case analyses
10
11 and 2) arm-level assumption analyses, where the relative incidence among those
12
13 with missing data was assigned the same incidence as those followed-up in the
14
15 same arm ($RI_{LTFU/FU} = 1$)¹⁶.
16
17
18
19

20
21
22 A complete case analysis was performed for long-term function and was
23
24 summarized using Standard Mean Differences (SMDs). The SMDs were
25
26 weighted according to the inverse variance method and pooled with a random-
27
28 effects model^{12,17,18}. Minimal important differences (MIDs) were incorporated to
29
30 aid the interpretation of treatment effects. The MID describes the smallest effect
31
32 that an informed patient would perceive as beneficial enough to justify a change
33
34 in management¹⁹⁻²³. The MID for the DASH questionnaire is estimated to be 10.2
35
36 points^{24,25}, which was converted to units of SD using the DASH median SD for
37
38 each comparison²⁶. A zone of clinical equivalence based on the converted MID
39
40 was projected onto the forest plot to aid interpretability of the pooled SMDs.
41
42
43
44
45

46
47
48 We quantified heterogeneity using the X^2 test for heterogeneity and the I^2
49
50 statistic¹². We developed a priori hypotheses to explain potentially high
51
52 heterogeneity in treatment effects across trials between intramedullary and plate
53
54 fixation, between immediate and delayed (1-4 weeks) surgical intervention,
55
56
57
58
59
60

1
2
3 between two fragment and comminuted fractures, and between the presence or
4
5 absence of selection and/or detection bias.
6
7

8
9
10 The Cohen κ (kappa) coefficient was used to evaluate agreement between the
11
12 two reviewers for full text screening and a weighted κ coefficient was used to
13
14 evaluate inter-observer agreement between the two reviewers for the risk of bias
15
16 assessment^{27,28}; all coefficients were calculated using SPSS software (version
17
18 21.0; SPSS Inc.). All tests of significance were 2-tailed, and p values of less than
19
20 0.05 were considered significant. To assess for publication bias, we visually
21
22 inspected a funnel plot for the outcome of long-term function¹². The forest plots
23
24 and funnel plot were generated using Review Manager software (RevMan
25
26 version 5.2; Nordic Cochrane Centre, Cochrane Collaboration, 2012).
27
28
29
30
31
32

33 **RESULTS**

34 **Included Studies**

35
36 The electronic literature search identified 422 potentially relevant citations.
37
38 Fifteen of these studies proved eligible for inclusion (Figure 1). The overall
39
40 agreement between reviewers for final eligibility was excellent ($\kappa = 0.94$, 95% CI
41
42 0.84 to 1).
43
44
45
46
47
48

49 **Study Characteristics**

50
51 All fifteen studies included in this review were published between 2007 and 2013
52
53 (Table 1). Nine studies compared operative with nonoperative treatment. Five
54
55
56
57
58
59
60

1
2
3 studies compared different operative implants²⁹⁻³³. One placebo-controlled trial
4 managed all fractures nonoperatively³⁴. Twelve studies were reported in English.
5
6 The three studies that were not in English were translated by reviewers with
7
8 methodological expertise^{30,35,36}. Eight studies were considered to be at *low* risk
9
10 for attrition bias, six were classified as *high* risk, and one was judged as unclear
11
12 (Figure 2). Agreement between reviewers in the assessment of study
13
14 methodological quality was excellent, weighted $\kappa = 0.85$. The funnel plot did not
15
16 suggest publication bias (Figure 3); however, the sample of only eight
17
18 studies^{5,10,35,37-41} limits interpretability¹².
19
20
21
22
23
24
25
26

27 **OPERATIVE VERSUS NONOPERATIVE MANAGEMENT**

28 **Secondary Procedures**

29
30 Nonoperative treatment did not confer a greater risk of secondary operations
31
32 across 8 trials involving 685 patients (RR 1.16, 95% CI 0.58 to 2.35, $p = 0.67$;
33
34 heterogeneity $p = 0.08$, $I^2 = 50\%$) (Figure 4). Subgroup analyses suggested an
35
36 interaction between the type of operative implants (plate versus intramedullary
37
38 fixation) and the need for secondary operation ($p = 0.05$). These findings were
39
40 robust to sensitivity testing (complete-case and $R_{LTFU/FU} = 1$ analyses) for those
41
42 trials with missing data. Reoperations in the operative group commonly included
43
44 hardware irritation (54.8%), infection (19%) and implant failure/refracture (19%).
45
46 Common indications for secondary procedures in nonoperatively managed
47
48 patients were symptomatic nonunion (57.1%) and symptomatic malunion
49
50 (28.6%).
51
52
53
54
55
56
57
58
59
60

All Complications

Across eight studies, there were 77 (23%) complications in 340 operatively treated patients and 88 (26%) complications in 345 nonoperatively treated patients (Table 2). Operative and nonoperative treatments did not differ in complication risk (RR 0.90, 95% CI 0.55 to 1.50, $p = 0.70$; heterogeneity $p = 0.01$, $I^2 = 63\%$) (Figure 5). Between trial heterogeneity was not explained by subgroup analysis for type of operative implant ($p = 0.15$). Sensitivity testing (complete-case and $R_{LTFU/FU} = 1$ analyses) for those trials with missing data conferred a similar result.

Functional scores

All studies in the pooled analysis evaluated function at 1-year with the exception of one trial⁴⁰, which assessed shoulder function at 2 years. Long-term function favored operatively treated patients (SMD 0.38, 95% CI 0.00 to 0.75, $p = 0.05$; heterogeneity $p = 0.0001$, $I^2 = 79\%$) (Figure 6); however, the pooled estimate did not exceed the threshold of ± 1.33 SD for the MID. Subgroup analyses to assess the potential risk of selection bias and attrition bias for overall function at one year or more did not differ appreciably from the prior analysis.

OPERATIVE INTERVENTIONS

Comparison of surgical implants with respect to indications for reoperations, all other complications and long-term function have been summarized in Table 3.

1
2
3 The functional outcome at 1-year was similar between groups in all trials,
4 demonstrating no significant difference irrespective of the implant used for
5 internal fixation.
6
7
8
9

10 11 12 **NONOPERATIVE TREATMENTS**

13
14
15 The available evidence for conservative treatment of acute displaced midshaft
16 clavicle fractures from a placebo-controlled trial of high methodological quality
17 found no differences in clinical fracture healing between LIPUS and placebo³⁴.
18
19 The study reported nine (4 placebo, 5 active) out of 101 (8.9%) patients who
20 completed the study underwent subsequent operative treatment with open
21 reduction and internal fixation (ORIF) for fractures that did not heal according to
22 the patients.
23
24
25
26
27
28
29
30
31
32
33

34 **INTERPRETATION**

35 **Key Findings**

36
37 This meta-analysis assessing the relative effects of operative versus
38 nonoperative intervention for acute displaced midshaft clavicle fractures
39 suggested that the incidence of secondary operations and all other complications
40 were similar in both the operative and nonoperative groups. There was modest
41 functional improvement at 1 year in operatively treated patients, however this
42 finding did not reach clinical significance. Based on the GRADE criteria (Table 4),
43 the current systematic review and meta-analysis found a lack of high-quality
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 evidence to inform the management of acute displaced midshaft clavicle
4
5 fractures.
6
7
8
9

10 A previous systematic review captured secondary procedures¹ and reported a
11 pooled estimate of effect reported as a RR of 0.38, 95% CI 0.15 to 0.99, favoring
12 the operative group, a finding that is inconsistent with our review. Our review
13 added a recent RCT and increased the pooled sample size by over one third,
14 likely explaining, in part, the inconsistency. This discrepancy may be further
15 explained by the fact that our review captured hardware irritation and infection as
16 indications for non-routine secondary procedures, whereas Lenza et al., 2013¹
17 did not.
18
19
20
21
22
23
24
25
26
27
28
29
30
31

32 **Limitations**

33
34 While our population was homogenous in terms of major demographic
35 characteristics, heterogeneity was identified across our key outcomes (I^2 of 50% -
36 79%). Although operative treatment with plates and screws, and intramedullary
37 devices are technically distinct from each other, pooling them separately did not
38 explain the high heterogeneity seen in the primary analyses. Seven out of the
39 fifteen trials included in this review had inadequately addressed those patients
40 who were lost to follow-up. Markedly, a greater number of patients lost to follow-
41 up were in the nonoperative group of the trials comparing operative to
42 nonoperative treatment, which may limit the precision of our estimates of
43 treatment effects and thus overall generalizability.
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Implications for practice

Adopting a policy of routine internal fixation for acute displaced midshaft clavicle fractures is contentious, as surgery carries the burden of greater hospital expenditures, as well as inherent surgical complications, including deep or superficial wound infection, hardware irritation, hardware failure or migration, and poor cosmesis of a surgical scar^{9,41}. A recent retrospective population-based study conducted in Ontario, Canada of 1350 patients treated with ORIF for a closed isolated midshaft clavicle fracture conducted by Leroux et al., 2014 reported a reoperation rate (24.6%), which is approximately twice as high as our findings⁴². Fifty percent of patients had their hardware removed after 12 months (median 12, months; IQR, 5.8 to 16.1 months), whereas more than half of the trials included in this meta-analysis had a follow-up period of only 12 months. The inclusion of data from non-academic institutions and longer follow-up in this retrospective analysis could potentially explain the higher reoperation rate compared to the RCTs included in this study, and nonetheless could have profound clinical implications.

Implications for research

If long-term function is seemingly similar between treatment groups then further investigation should aim to determine if early functional improvements (<6 months) in operatively treated patients significantly differ from those patients treated nonoperatively. The most recent RCT included in our review evaluated

1
2
3 absence from work, and found that although the timing of return to work was
4
5 dependent on the nature of the patients' work, no significant differences were
6
7 found between the two groups in terms of total time off work following injury ($p =$
8
9 0.7)⁵.

10
11
12
13
14
15 The trials included in our review did not provide sufficient evidence to suggest
16
17 which patients would benefit most from surgical treatment. It still remains unclear
18
19 whether certain fracture characteristics such as shortening, displacement or
20
21 comminution can reliably predict patient-focused functional outcomes⁴³. A
22
23 reliability study amongst fellowship-trained shoulder and sports medicine
24
25 orthopedic surgeons demonstrated moderate to strong agreement for both
26
27 degree of displacement and comminution; however, standard plain unilateral
28
29 radiographs of the clavicle were insufficient to reliably determine the degree of
30
31 shortening of clavicle fractures and the need for surgery among this cohort⁴⁴.
32
33
34
35
36 Further investigations are required to develop better criteria to avoid under- or
37
38 overestimating fracture severity. Thereby, focusing the utilization of surgical
39
40 resources on appropriate candidates and preventing under-treatment of the injury
41
42 nonoperatively.
43
44
45
46
47

48 **CONCLUSIONS**

49
50 Routine use of internal fixation for the treatment of these injuries may not be
51
52 entirely consistent with current best evidence. Evidence for the type of implant or
53
54
55
56
57
58
59
60

1
2
3 approach to nonoperative treatment remains inconclusive and complication rates
4
5 high regardless of the management approach.
6
7
8
9

10 **Conflict of Interests:** There was no funding for this study.
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Confidential

References

1. Lenza MB, R.; Johnston, R. V.; Belloti, J. C.; Faloppa, F. Surgical versus conservative interventions for treating fractures of the middle third of the clavicle. *The Cochrane database of systematic reviews*. 2013; 6: CD009363.
2. McKee MD. Clavicle Fractures in 2010: Sling/Swathe or Open Reduction and Internal Fixation? *Orthopedic Clinics of North America*. 2010; 41: 225-31.
3. Nordqvist A and Petersson C. The incidence of fractures of the clavicle. *Clin Orthop Relat Res*. 1994: 127-32.
4. Nowak J, Mallmin H and Larsson S. The aetiology and epidemiology of clavicular fractures. A prospective study during a two-year period in Uppsala, Sweden. *Injury*. 2000; 31: 353-8.
5. Robinson CMG, E. B.; Murray, I. R.; Jenkins, P. J.; Ahktar, M. A.; Read, E. O.; Foster, C. J.; Clark, K.; Brooksbank, A. J.; Arthur, A.; Crowther, M. A.; Packham, I.; Chesser, T. J. Open reduction and plate fixation versus nonoperative treatment for displaced midshaft clavicular fractures: a multicenter, randomized, controlled trial. *The Journal of bone and joint surgery*. 2013; American volume. 95: 1576-84.
6. Van Tassel D, Owens BD, Pointer L and Moriatis Wolf J. Incidence of clavicle fractures in sports: analysis of the NEISS Database. *International journal of sports medicine*. 2014; 35: 83-6.
7. Neer CS, 2nd. Nonunion of the clavicle. *Journal of the American Medical Association*. 1960; 172: 1006-11.
8. Rowe CR. An atlas of anatomy and treatment of midclavicular fractures. *Clin Orthop Relat Res*. 1968; 58: 29-42.
9. McKee RCW, D. B.; Schemitsch, E. H.; McKee, M. D. Operative versus nonoperative care of displaced midshaft clavicular fractures: A meta-analysis of randomized clinical trials. *Journal of Bone and Joint Surgery - Series A*. 2012; 94: 675-84.
10. Canadian Orthopaedic Trauma S. Nonoperative treatment compared with plate fixation of displaced midshaft clavicular fractures. A multicenter, randomized clinical trial. *J Bone Joint Surg Am*. 2007; 89: 1-10.
11. Xu JX, L.; Xu, W.; Gu, Y.; Xu, J. Operative versus nonoperative treatment in the management of midshaft clavicular fractures: a meta-analysis of randomized controlled trials. *J Shoulder Elbow Surg*. 2014; 23: 173-81.
12. Jpt CHH and Green S. Cochrane handbook for systematic reviews of interventions version 5.1. 0 [updated March 2011]. *The Cochrane Collaboration*. 2011.
13. Moher D, Liberati A, Tetzlaff J and Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *Annals of internal medicine*. 2009; 151: 264-9.
14. Wilczynski NL, McKibbin KA and Haynes RB. Enhancing retrieval of best evidence for health care from bibliographic databases: calibration of the hand search of the literature. *Studies in health technology and informatics*. 2001; 84: 390-3.

15. Guyatt GH, Oxman AD, Kunz R, Vist GE, Falck-Ytter Y and Schunemann HJ. What is "quality of evidence" and why is it important to clinicians? *Bmj*. 2008; 336: 995-8.
16. Akl EA, Johnston BC, Alonso-Coello P, et al. Addressing dichotomous data for participants excluded from trial analysis: a guide for systematic reviewers. *PloS one*. 2013; 8: e57132.
17. DerSimonian R and Laird N. Meta-analysis in clinical trials. *Controlled clinical trials*. 1986; 7: 177-88.
18. Puhan MA, Soesilo I, Guyatt GH and Schunemann HJ. Combining scores from different patient reported outcome measures in meta-analyses: when is it justified? *Health and quality of life outcomes*. 2006; 4: 94.
19. Bannuru RR, Vaysbrot EE and McIntyre LF. Did the American Academy of Orthopaedic Surgeons osteoarthritis guidelines miss the mark? *Arthroscopy*. 2014; 30: 86-9.
20. Carragee EJ. The rise and fall of the "minimum clinically important difference". *The spine journal : official journal of the North American Spine Society*. 2010; 10: 283-4.
21. Copay AG, Subach BR, Glassman SD, Polly DW, Jr. and Schuler TC. Understanding the minimum clinically important difference: a review of concepts and methods. *The spine journal : official journal of the North American Spine Society*. 2007; 7: 541-6.
22. Gatchel RJ and Mayer TG. Testing minimal clinically important difference: consensus or conundrum? *The spine journal : official journal of the North American Spine Society*. 2010; 10: 321-7.
23. Jaeschke R, Singer J and Guyatt GH. Measurement of health status. Ascertaining the minimal clinically important difference. *Controlled clinical trials*. 1989; 10: 407-15.
24. Angst F, Schwyzer H-K, Aeschlimann A, Simmen BR and Goldhahn J. Measures of adult shoulder function: Disabilities of the Arm, Shoulder, and Hand Questionnaire (DASH) and Its Short Version (QuickDASH), Shoulder Pain and Disability Index (SPADI), American Shoulder and Elbow Surgeons (ASES) Society Standardized Shoulder Assessment Form, Constant (Murley) Score (CS), Simple Shoulder Test (SST), Oxford Shoulder Score (OSS), Shoulder Disability Questionnaire (SDQ), and Western Ontario Shoulder Instability Index (WOSI). *Arthritis Care & Research*. 2011; 63: S174-S88.
25. Schmitt JS and Di Fabio RP. Reliable change and minimum important difference (MID) proportions facilitated group responsiveness comparisons using individual threshold criteria. *J Clin Epidemiol*. 2004; 57: 1008-18.
26. Thorlund K, Walter SD, Johnston BC, Furukawa TA and Guyatt GH. Pooling health-related quality of life outcomes in meta-analysis—a tutorial and review of methods for enhancing interpretability. *Research Synthesis Methods*. 2011; 2: 188-203.
27. Landis JR and Koch GG. The measurement of observer agreement for categorical data. *Biometrics*. 1977; 33: 159-74.
28. Orwin RG. Evaluating coding decisions. 1994: 139-62.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
29. Assobhi JE. Reconstruction plate versus minimal invasive retrograde titanium elastic nail fixation for displaced midclavicular fractures. *J*. 2011; 12: 185-92.
30. Bi HZY, M. Q.; Tan, Y. C.; Fu, S. The randomized controlled trial of the treatment for clavicular fracture by rotatory manual reduction with forceps holder and retrograde percutaneous pinning transfixation. [Chinese]. *Zhongguo gu shang = China journal of orthopaedics and traumatology*. 2008; 21: 490-3.
31. Ferran NAH, P.; Vannet, N.; Williams, R.; Evans, R. O. Locked intramedullary fixation vs plating for displaced and shortened mid-shaft clavicle fractures: A randomized clinical trial. *Journal of Shoulder and Elbow Surgery*. 2010; 19: 783-9.
32. Jiang HQ, W. Operative treatment of clavicle midshaft fractures using a locking compression plate: Comparison between mini-invasive plate osteosynthesis (MIPPO) technique and conventional open reduction. *Orthopaedics and Traumatology: Surgery and Research*. 2012; 98: 666-71.
33. Shen JWT, P. J.; Qu, H. B. A three-dimensional reconstruction plate for displaced midshaft fractures of the clavicle. *J Bone Joint Surg Br*. 2008; 90: 1495-8.
34. Lubbert PHvdR, R. H.; Hoorntje, L. E.; van der Werken, C. Low-intensity pulsed ultrasound (LIPUS) in fresh clavicle fractures: a multi-centre double blind randomised controlled trial. *Injury*. 2008; 39: 1444-52.
35. Figueiredo EAN, E. J.; Yoshizawa, HJunior; Neto, Dall'Ara; Birth, L. F.; Faria Matta, G. H.; et al.,. Prospective randomized study comparing surgical treatments using anterior plate and non-surgical management of fractures of the middle third of the clavicle. *Rev bras ortop*. 2008; 43.
36. Koch HJR, C.; Tonus, C.; Witzel, K. The intramedullary osteosynthesis of the diaphyseal fracture of the clavicle compared to conservative treatment. *Deutsche Zeitschrift fur Sportmedizin*. 2008; 59: 91-4.
37. Chen QYK, D. Q.; Cheng, X. J.; Zhang, W.; Wang, W.; Lin, Z. Q.; Cheng, S. W.; Shen, Y.; Ying, X. Z.; Peng, L.; Lv, C. Z. Intramedullary nailing of clavicular midshaft fractures in adults using titanium elastic nail. *Chin J Traumatol*. 2011; 14: 269-76.
38. Judd DBP, M. P.; Smith, E.; Bottoni, C. R. Acute operative stabilization versus nonoperative management of clavicle fractures. *American journal of orthopedics (Belle Mead, NJ)*. 2009; 38: 341-5.
39. Mirzatolooei F. Comparison between operative and nonoperative treatment methods in the management of comminuted fractures of the clavicle. *Acta Orthopaedica et Traumatologica Turcica*. 2011; 45: 34-40.
40. Smekal VI, A.; Struve, P.; Wambacher, M.; Krappinger, D.; Kralinger, F. S. Elastic stable intramedullary nailing versus nonoperative treatment of displaced midshaft clavicular fractures—a randomized, controlled, clinical trial. *Journal of orthopaedic trauma*. 2009; 23: 106-12.
41. Virtanen KJR, V.; Pajarinen, J.; Savolainen, V.; Bjorkenheim, J. M.; Paavola, M. Sling compared with plate osteosynthesis for treatment of displaced midshaft clavicular fractures: A randomized clinical trial. *Journal of Bone and Joint Surgery - Series A*. 2012; 94: 1546-53.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

42. Leroux T, Wasserstein D, Henry P, et al. Rate of and Risk Factors for Reoperations After Open Reduction and Internal Fixation of Midshaft Clavicle Fractures. *The Journal of Bone & Joint Surgery*. 2014; 96: 1119-25.

43. Evaniew N, Simunovic N, McKee MD and Schemitsch E. Cochrane in CORR : Surgical Versus Conservative Interventions for Treating Fractures of the Middle Third of the Clavicle. *Clin Orthop Relat Res*. 2014.

44. Jones GL, Bishop JY, Lewis B and Pedroza AD. Intraobserver and interobserver agreement in the classification and treatment of midshaft clavicle fractures. *Am J Sports Med*. 2014; 42: 1176-81.

Confidential

Appendix 1. Example search strategy – MEDLINE via OVID

1. Clavicle/
2. clavic*.mp.
3. collarbone*.mp.
4. or/1-3
5. exp Fractures, Bone/
6. exp Fracture Healing/
7. exp Fracture Fixation/
8. fracture*.mp.
9. Surgical Procedures, Operative/
10. exp Orthopedic Procedures/
11. Surgery.fs.
12. Orthopedic Fixation Devices/
13. surgical.mp.
14. surger*.mp.
15. operative.mp.
16. intramedullary.mp.
17. open reduction.mp.
18. internal fixation.mp.
19. plate*.mp.
20. nonoperative.mp.
21. non-operative.mp.
22. conservative.mp.
23. sling*.mp.
24. or/5-23
25. 4 and 24
26. randomized controlled trial.pt.
27. randomized.mp.
28. placebo.mp.
29. or/26-28
30. 25 and 29
31. limit 30 to animals
32. limit 31 to humans
33. 31 not 32
34. 30 not 33

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 1. Study flow diagram

	Random sequence generation (selection bias)	Allocation concealment (selection bias)	Blinding of participants and personnel (performance bias)	Blinding of outcome assessment (detection bias)	Incomplete outcome data (attrition bias)	Selective reporting (reporting bias)	Other bias
Assobhi 2011	?	+	-	-	+	-	+
Bi 2008	+	?	?	?	?	-	?
Chen 2011	?	?	-	-	+	-	+
COTS 2007	+	+	-	-	-	-	?
Ferran 2010	?	+	-	-	-	?	+
Figueiredo 2008	+	?	-	-	-	?	+
Jiang 2012	?	?	-	-	+	?	+
Judd 2009	+	?	-	-	-	?	+
Koch 2008	?	?	-	-	+	?	+
Lubbert 2008	+	+	+	+	+	?	+
Mirzatoaloei 2011	+	+	-	-	-	-	?
Robinson 2013	+	?	-	-	+	+	+
Shen 2008	+	?	?	+	-	-	+
Smekal 2009	+	?	-	-	+	-	+
Virtanen 2012	?	+	-	-	+	+	+

Figure 2. Risk-of-bias assessment of randomized controlled trials in the meta-analysis

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 3. Funnel Plot of long-term function in trials of operative versus non-operative treatment
Note: SMD = standardized mean difference

Confidential




Figure 4. Pooled estimates of secondary surgery between operative and nonoperative groups

Note: Figueiredo et al., 2008; n =24 (operative), n=16 (nonoperative) are number completed for this study, and not the number initially randomized. CI = confidence interval

Confidential




Figure 5. Pooled estimates of all other complications between operative and nonoperative groups

Note: Figueiredo et al., 2008; n =24 (operative), n=16 (nonoperative) are number completed for this study, and not the number initially randomized. CI = confidence interval

Confidential




Figure 6. Pooled long-term (≥ 1 year) function following operative and non-operative treatment

Note: Red lines show a zone of clinical equivalence based on a minimal important difference of 10.2 points on the DASH questionnaire. Standardized mean differences greater than zero favor operative treatment. CI = confidence interval

Confidential

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Confidential

Table 1. Characteristics of included studies

Study	Country	Sample size	Males (%)	Age (mean)	Length of Follow-up ‡	Intervention	Comparison
Chen et al., 2011 ³⁷	China	60	53	38.7	15 (10-20)	TEN	Sling
COTS 2007 ¹⁰	Canada	132	78	33.5	12 [*]	Open reduction plate fixation†	Sling
Figueiredo et al., 2008 ³⁵	Brazil	50	78	30.2	24	DCP AI plate	Sling
Judd et al., 2009 ³⁸	United States	57	91	26.5	12	Modified Hagie pin	Sling
Koch et al., 2008 ³⁶	Germany	68	66	35.4	19.1 (8-26)	Intramedullary pin	Figure of 8 dressing
Mirzatooei 2011 ³⁹ §	Iran	60	82	35.6	12	Reconstruction plate on superior surface	Sling
Robinson et al., 2013 ⁵	United Kingdom	200	88	32.4	12	Locking plate	Collar and Cuff
Smekal et al., 2009 ⁴⁰	Austria	68	87	37.7	24	TEN	Sling
Virtanen et al., 2012 ⁴¹	Finland	60	87	36.7	12	Reconstruction plate on anterior surface	Sling
Assobhi et al., 2011 ²⁹	Egypt	38	87	31.5	12	AI reconstruction plate	RTEN
Bi et al., 2008 ³⁰	China	201	72	39.8	10.6 (4-21)	Retrograde percutaneous pin	Kirshner pin
Ferran et al., 2010 ³¹	United Kingdom	133	84	29.2	12	LCDCP	Rockwood pin
Jiang et al., 2012 ³² §	China	64	63	42.5	24	LCP	MIPPO
Shen et al., 2008 ³³	China	32	56	44.2	12	Superior reconstruction plate	3D contoured cortical plate
Lubbert et al., 2008 ³⁴	Netherlands	120	84	NR	12	LIPUS	Placebo

Note: NR = Not reported, TEN = Titanium elastic nail, DCP AI = Dynamic compression plate in antero-inferior position, N/A = Not applicable, AI = antero-inferior surface, RTEN = retrograde titanium elastic nail, LCP = locking compression plate, MIPPO = minimally invasive percutaneous plate osteosynthesis, LCDCP = limited contact dynamic compression plate

§ Only enrolled patients with comminuted fractures (3 or more fragments)

† Open reduction and plate fixation (44 patients with limited contact dynamic compression plates; 15 with 3.5 mm reconstruction plates; four with pre-contoured plates, and four with other plates)

‡ Longest follow-up; Chen et al., 2011, Koch et al., 2008, Bi et al., 2008 reported as mean (range)

*Data for two years in a subsequent publication (Schemitsch et al., 2011)

Table 2. All other complications

Study	Operative Group (N = 340 Patients)	Nonoperative group (N = 345 Patients)
COTS 2007 ¹⁰	9 operative procedures 2 symptomatic nonunions 8 neurologic symptoms 2 abnormality of the AC or SC joint 2 other (not described)	18 operative procedures 7 neurologic symptoms 1 complex regional pain syndrome 3 abnormality of the AC or CV joint 2 other (not described)
Figueiredo et al., 2008 ³⁵	2 symptomatic nonunions 1 implant failure	1 symptomatic nonunion 2 adhesive capsulitis
Judd et al., 2009 ³⁸	6 operative procedures 1 refracture 3 wound infections 1 neurologic symptoms	1 operative procedure 1 refracture
Koch et al., 2008 ³⁶	NR	NR
Mirzatooei 2011 ³⁹	2 operative procedures 4 symptomatic malunions 1 early mechanical failure	19 symptomatic malunions 2 neurologic symptoms
Robinson et al., 2013 ⁵	16 operative procedures 2 wound infections 1 wound dehiscence 2 rotator cuff impingement	17 operative procedures 1 rotator cuff impingement
Smekal et al., 2009 ⁴⁰	9 operative procedures	5 operative procedures 3 neurologic symptoms
Virtanen et al., 2012 ⁴¹	1 refracture 1 early mechanical failure 1 hardware irritation	1 operative procedure 2 symptomatic malunions 2 refractures
Total Complications	77	88

Note: NR = Not reported, AC = Acromioclavicular, SC = Sternoclavicular

Table 3. Summary of secondary operation and complication rates, and functional outcome for trials comparing operative interventions

Study	Secondary Operations	RR (95% CI)	Complications not requiring surgical intervention	RR (95% CI)	Functional Outcome: Constant Score (1 year)	MD (95% CI)
Assobhi et al., 2011²⁹						
AI reconstruction plate (n = 19)	1 nonunion 1 wound infection and implant loosening	0.67 (0.13 to 3.55)	1 nonunion	1.00 (0.23 to 4.34)	89.8 (11.3)	-5.60 (-11.21 to 0.01)
RTEN (n = 19)	3 prominent nails		NR		95.5 (5.3)	
Bi et al., 2011³⁰						
Retrograde percutaneous pin (n = 101)	NR	NA	NR	0.11 (0.01 to 2.02)	NR	NA
Kirshner pin (n = 100)	NR		4 nonunions		NR	
Ferran et al., 2010³¹						
Rockwood pin (n = 17)	1 implant loosening	0.22 (0.06 to 0.88)	NR	0.22 (0.06 to 0.88)	92.1 (6)*	3.4 (-2.02 to 8.82)
LCDCP (n = 15)	3 superficial infections 1 persistent pain 4 hardware irritation		NR		88.7 (9.1)*	
Jiang et al., 2012³²						
MIPPO (n = 32)	NR	NA	NR	NA	96†	0.30 (-4.70 to 5.30)
LCP (n = 32)	NR		NR		95.7†	
Shen et al., 2008³³						
3D contoured cortical plate (n = 67)	1 delayed union	0.12 (0.02 to 0.96)	3 'symptomatic patients'	0.20 (0.06 to 0.65)	NR	NA
Superior reconstruction plate (n = 66)	8 delayed unions		15 'symptomatic patients'			

Note: NR = Not reported, NA = Not applicable, AI = antero-inferior surface, RTEN = retrograde titanium elastic nail, LCP = locking compression plate, MIPPO = minimally invasive percutaneous plate osteosynthesis, LCDCP = limited contact dynamic compression plate

*Unclear as to whether or not this was at 1-year assessment

†No standard deviation reported; means were abstracted from graphical analyses

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

Table 4. GRADE summary of findings for operative compared with nonoperative treatment for acute displaced midshaft clavicle fractures

Patient or population: patients with an acute displaced midshaft clavicle fracture			
Intervention: Operative treatment (plate or intramedullary device)			
Comparison: Nonoperative treatment (standard sling, figure of eight dressing, or a collar and cuff)			
Outcomes: Secondary operations, all other complications, long-term function			
Outcomes	No. of participants (studies)	Anticipated effects, risk with operative treatment (95% CI)	GRADE quality of evidence
Secondary operations Follow-up: 12 months	685 (8)	Evidence suggested higher incidence of secondary surgery (RR 1.16, 95% CI 0.58 to 2.35) in the operative group, but this was not statistically significant	⊕⊕⊕⊖ low*<!--‡</b-->
All other complications Follow-up: 12 months	685 (8)	Evidence suggested a slightly lower number of complications (RR 0.9, 95% CI 0.55 to 1.5) in the operative group, but this was not statistically significant	⊕⊕⊕⊖ low*‡
Long-term function Follow-up: (≥ 1 year)	611 (8)	Mean long-term shoulder function was 0.38 SDs higher (0.22 lower to 0.54 higher)†	⊕⊖⊖⊖ very low*§
<p>Note: CI = confidence interval, GRADE = Grading of Recommendations Assessment, Development, and Evaluation, RR = risk ratio, SMD = standardized mean difference, SD = standard deviation, MID = minimal important difference</p> <p>*Downgraded because of risk of bias (lack of blinding study personnel, unclear reporting of allocation concealment and sequence generation)</p> <p>†Effect failed to exceed minimal important difference (smallest effect that an informed patient would perceive as beneficial enough to justify a change in management)</p> <p>‡Downgraded because of fragility of few events</p> <p>§Downgraded for imprecision and inconsistency</p>			
<p>GRADE Working Group grades of evidence</p> <p>High quality: Further research is very unlikely to change our confidence in the estimate of effect.</p> <p>Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.</p> <p>Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.</p> <p>Very low quality: We are very uncertain about the estimate.</p>			



PRISMA 2009 Checklist

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

Section/topic	#	Checklist item	Reported on page #
TITLE			
Title	1	Identify the report as a systematic review, meta-analysis, or both.	1
ABSTRACT			
Structured summary	2	Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.	2-3
INTRODUCTION			
Rationale	3	Describe the rationale for the review in the context of what is already known.	4
Objectives	4	Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).	4
METHODS			
Protocol and registration	5	Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.	N/A
Eligibility criteria	6	Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.	6
Information sources	7	Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.	5
Search	8	Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.	21
Study selection	9	State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).	6
Data collection process	10	Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.	6-7
Data items	11	List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.	6-7
Risk of bias in individual studies	12	Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.	7
Summary measures	13	State the principal summary measures (e.g., risk ratio, difference in means).	7-8
Synthesis of results	14	Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I^2) for each meta-analysis.	8-9

For Peer Review Only



PRISMA 2009 Checklist

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

Section/topic	#	Checklist item	Reported on page #
Risk of bias across studies	15	Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).	8-9
Additional analyses	16	Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.	8-9
RESULTS			
Study selection	17	Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.	9-10
Study characteristics	18	For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.	10
Risk of bias within studies	19	Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).	10
Results of individual studies	20	For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.	10-12
Synthesis of results	21	Present results of each meta-analysis done, including confidence intervals and measures of consistency.	10-11
Risk of bias across studies	22	Present results of any assessment of risk of bias across studies (see Item 15).	10
Additional analysis	23	Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).	10-11
DISCUSSION			
Summary of evidence	24	Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).	12-13
Limitations	25	Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).	13-14
Conclusions	26	Provide a general interpretation of the results in the context of other evidence, and implications for future research.	14-16
FUNDING			
Funding	27	Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.	16

From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(6): e1000097. doi:10.1371/journal.pmed1000097

For more information, visit: www.prisma-statement.org.